All patients
Age < 65y (younger) Age > 65y BRAF mutant BRAF wild type ECOG 0 ECOG 1 Gender, female Gender, male LDH > ULN LDH ≤ULN previous systemic treatment (%) previous systemic treatment NO (%) stage M0 stage M0/M1A/M1B stage M1A stage M1B stage M1C stage M1C (with brain metastasis)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
mML - L2 - all population, ipilimumab based treatment vs. chemotherapy, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CA184-024, 2011 0.72 [0.59; 0.87]
0.72 [0.59 ; 0.87 ] CA184-024, 2011 1 0% 502 NA not evaluable deaths (OS) (extension)detailed results CA184-024, 2011 0.69 [0.57; 0.84]
0.69 [0.57 ; 0.84 ] CA184-024, 2011 1 0% NA not evaluable progression or deaths (PFS)detailed results CA184-024, 2011 0.76 [0.63; 0.92]
0.76 [0.63 ; 0.92 ] CA184-024, 2011 1 0% 502 NA not evaluable DCRdetailed results CA184-024, 2011 1.15 [0.79; 1.68]
1.15 [0.79 ; 1.68 ] CA184-024, 2011 1 0% 502 NA not evaluable objective responses (ORR)detailed results CA184-024, 2011 1.56 [0.91; 2.65]
1.56 [0.91 ; 2.65 ] CA184-024, 2011 1 0% 502 NA not evaluable AE (any grade)detailed results CA184-024, 2011 5.17 [1.48; 18.09]
5.17 [1.48 ; 18.09 ] CA184-024, 2011 1 0% 498 NA not evaluable AE (grade 3-4)detailed results CA184-024, 2011 3.39 [2.34; 4.94]
3.39 [2.34 ; 4.94 ] CA184-024, 2011 1 0% 498 NA not evaluable AE leading to death (grade 5)detailed results CA184-024, 2011 1.02 [0.02; 51.42]
1.02 [0.02 ; 51.42 ] CA184-024, 2011 1 0% 498 NA not evaluable TRAE (any grade)detailed results CA184-024, 2011 5.64 [3.80; 8.35]
5.64 [3.80 ; 8.35 ] CA184-024, 2011 1 0% 498 NA not evaluable TRAE (grade 3-4)detailed results CA184-024, 2011 11.25 [6.30; 20.10]
11.25 [6.30 ; 20.10 ] CA184-024, 2011 1 0% 498 NA not evaluable Colitis TRAE (grade 3-4)detailed results CA184-024, 2011 10.35 [0.56; 190.49]
10.35 [0.56 ; 190.49 ] CA184-024, 2011 1 0% 498 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results CA184-024, 2011 21.14 [1.23; 363.94]
21.14 [1.23 ; 363.94 ] CA184-024, 2011 1 0% 498 NA not evaluable Hepatitis TRAE (grade 3-4)detailed results CA184-024, 2011 8.25 [0.43; 156.83]
8.25 [0.43 ; 156.83 ] CA184-024, 2011 1 0% 498 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results CA184-024, 2011 1.02 [0.02; 51.42]
1.02 [0.02 ; 51.42 ] CA184-024, 2011 1 0% 498 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results CA184-024, 2011 1.02 [0.02; 51.42]
1.02 [0.02 ; 51.42 ] CA184-024, 2011 1 0% 498 NA not evaluable Increase AST TRAE (grade 3-4)detailed results CA184-024, 2011 52.70 [7.19; 385.99]
52.70 [7.19 ; 385.99 ] CA184-024, 2011 1 0% 498 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results CA184-024, 2011 32.40 [7.79; 134.72]
32.40 [7.79 ; 134.72 ] CA184-024, 2011 1 0% 498 NA not evaluable Pruritus TRAE (grade 3-4)detailed results CA184-024, 2011 10.35 [0.56; 190.49]
10.35 [0.56 ; 190.49 ] CA184-024, 2011 1 0% 498 NA not evaluable Rash TRAE (grade 3-4)detailed results CA184-024, 2011 6.16 [0.31; 123.62]
6.16 [0.31 ; 123.62 ] CA184-024, 2011 1 0% 498 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results CA184-024, 2011 1.02 [0.02; 51.42]
1.02 [0.02 ; 51.42 ] CA184-024, 2011 1 0% 498 NA not evaluable Abdominal pain AE (grade 3-4)detailed results CA184-024, 2011 0.43 [0.11; 1.68]
0.43 [0.11 ; 1.68 ] CA184-024, 2011 1 0% 498 NA not evaluable Asthenia AE (grade 3-4)detailed results CA184-024, 2011 0.17 [0.02; 1.39]
0.17 [0.02 ; 1.39 ] CA184-024, 2011 1 0% 498 NA not evaluable Chills AE (grade 3-4)detailed results CA184-024, 2011 1.02 [0.02; 51.42]
1.02 [0.02 ; 51.42 ] CA184-024, 2011 1 0% 498 NA not evaluable Constipation AE (grade 3-4)detailed results CA184-024, 2011 1.02 [0.02; 51.42]
1.02 [0.02 ; 51.42 ] CA184-024, 2011 1 0% 498 NA not evaluable Cough AE (grade 3-4)detailed results CA184-024, 2011 2.04 [0.07; 60.99]
2.04 [0.07 ; 60.99 ] CA184-024, 2011 1 0% 498 NA not evaluable Decreased appetite AE (grade 3-4)detailed results CA184-024, 2011 0.76 [0.17; 3.43]
0.76 [0.17 ; 3.43 ] CA184-024, 2011 1 0% 498 NA not evaluable Diarrhoea AE (grade 3-4)detailed results CA184-024, 2011 21.14 [1.23; 363.94]
21.14 [1.23 ; 363.94 ] CA184-024, 2011 1 0% 498 NA not evaluable Dyspnoea AE (grade 3-4)detailed results CA184-024, 2011 16.77 [0.96; 293.61]
16.77 [0.96 ; 293.61 ] CA184-024, 2011 1 0% 498 NA not evaluable Fatigue AE (grade 3-4)detailed results CA184-024, 2011 2.44 [1.21; 4.94]
2.44 [1.21 ; 4.94 ] CA184-024, 2011 1 0% 498 NA not evaluable Headache AE (grade 3-4)detailed results CA184-024, 2011 4.12 [0.46; 37.08]
4.12 [0.46 ; 37.08 ] CA184-024, 2011 1 0% 498 NA not evaluable Increase AST AE (grade 3-4)detailed results CA184-024, 2011 18.42 [5.64; 60.14]
18.42 [5.64 ; 60.14 ] CA184-024, 2011 1 0% 498 NA not evaluable Increased ALT AE (grade 3-4)detailed results CA184-024, 2011 34.83 [8.39; 144.67]
34.83 [8.39 ; 144.67 ] CA184-024, 2011 1 0% 498 NA not evaluable Nausea AE (grade 3-4)detailed results CA184-024, 2011 1.36 [0.30; 6.14]
1.36 [0.30 ; 6.14 ] CA184-024, 2011 1 0% 498 NA not evaluable Pruritus AE (grade 3-4)detailed results CA184-024, 2011 10.35 [0.56; 190.49]
10.35 [0.56 ; 190.49 ] CA184-024, 2011 1 0% 498 NA not evaluable Pyrexia AE (grade 3-4)detailed results CA184-024, 2011 1.02 [0.02; 51.42]
1.02 [0.02 ; 51.42 ] CA184-024, 2011 1 0% 498 NA not evaluable Rash AE (grade 3-4)detailed results CA184-024, 2011 6.16 [0.31; 123.62]
6.16 [0.31 ; 123.62 ] CA184-024, 2011 1 0% 498 NA not evaluable Vomiting AE (grade 3-4)detailed results CA184-024, 2011 2.07 [0.61; 6.95]
2.07 [0.61 ; 6.95 ] CA184-024, 2011 1 0% 498 NA not evaluable Weight decreased AE (grade 3-4)detailed results CA184-024, 2011 1.02 [0.06; 16.34]
1.02 [0.06 ; 16.34 ] CA184-024, 2011 1 0% 498 NA not evaluable 0.0 100.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 03:50 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 69
- treatments: 850,329,558,579,549,868